10-Q: Gossamer Bio Reports First Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio reports a net loss of $36.6 million for Q1 2025, with revenue driven by the Chiesi collaboration and ongoing development of Seralutinib.

Summary

• Gossamer Bio, Inc. reported its financial results for the first quarter of 2025.
• The company is focused on developing and commercializing seralutinib for pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD).
• Gossamer Bio had cash, cash equivalents, and marketable securities totaling $257.9 million as of March 31, 2025.
• The company incurred a net loss of $36.6 million for the three months ended March 31, 2025, compared to a net loss of $41.9 million for the same period in 2024.
• Revenue for the quarter was $9.9 million, derived from the Chiesi Collaboration Agreement.
• Research and development expenses were $38.0 million, compared to $32.4 million in the prior year.
• General and administrative expenses decreased to $8.7 million from $9.6 million.
• The company believes its current financial resources will fund operations for at least the next 12 months.
• The Phase 3 PROSERA study in PAH is expected to have topline data reported in February 2026.
• The Phase 3 SERANATA study for PH-ILD is expected to have first clinical sites activated in Q4 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, the loss has decreased compared to the previous year, and the collaboration with Chiesi provides a stable revenue stream. The company also has sufficient cash to fund operations for the next 12 months. However, the need for future capital raises and the inherent risks of drug development temper the positive aspects.

Positives

• The net loss decreased from $41.9 million in Q1 2024 to $36.6 million in Q1 2025.
• The company has a collaboration agreement with Chiesi, providing revenue and cost-sharing.
• The company believes it has sufficient working capital to fund operations for at least the next 12 months.
• The company is progressing with Phase 3 clinical trials for seralutinib in PAH and PH-ILD.

Negatives

• The company incurred a net loss of $36.6 million for the quarter.
• The company has an accumulated deficit of $1,305.2 million as of March 31, 2025.
• The company expects to continue to incur significant operating losses for the foreseeable future.
• The company will need to raise additional capital through equity offerings, debt financings or other capital sources.

Risks

• The company may be unable to raise additional funds or enter into collaborations when needed.
• Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations.
• The company is dependent on the success of seralutinib.
• Changes to United States tariff and import/export regulations may have a negative effect on the company.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it continues the development of and seeks regulatory approvals for seralutinib. Management believes that it has sufficient working capital on hand to fund operations through at least the next 12 months from the date these unaudited condensed consolidated financial statements were available to be issued.

Industry Context

Gossamer Bio is operating in the competitive biopharmaceutical industry, specifically targeting pulmonary hypertension. The collaboration with Chiesi is a strategic move to share development costs and commercialize seralutinib. The success of seralutinib will depend on its efficacy, safety, and market acceptance compared to existing treatments.

Comparison to Industry Standards

• It is difficult to compare Gossamer Bio directly to industry standards without knowing the specific details of their clinical trial results and commercialization strategy.
• However, similar biopharmaceutical companies in the clinical stage often have high R&D expenses and net losses as they invest in drug development.
• The collaboration with Chiesi is a common strategy to mitigate risk and share costs, similar to deals made by companies like Acceleron Pharma (acquired by Merck) in the pulmonary hypertension space.
• The company's cash runway of at least 12 months is typical for companies of this size, but they will need to raise additional capital to continue development.

Stakeholder Impact

• Shareholders: The company's financial performance and progress in clinical trials will impact shareholder value.
• Employees: The company's financial stability and success of seralutinib will impact job security and opportunities.
• Patients: The successful development of seralutinib could provide a new treatment option for pulmonary hypertension.
• Collaborators: The collaboration with Chiesi will impact the development and commercialization of seralutinib.

Next Steps

• Continue Phase 3 PROSERA study in PAH and report topline data in February 2026.
• Activate first clinical sites for the Phase 3 SERANATA Study for PH-ILD in Q4 2025.
• Continue development and commercialization activities in relation to seralutinib and Licensed Products, under the global development plan and U.S. commercialization plan in accordance with the timelines therein.
• Continue to lead global development of seralutinib in PAH and PH-ILD, and the parties will equally share the costs for the activities included in the global development plan for all Licensed Products, with the exception of the PROSERA Phase 3 study, which the Company will be solely responsible for conducting at the Company's own cost and expense.

Key Dates

Keywords

seralutinib, pulmonary hypertension, PAH, PH-ILD, Chiesi, clinical trials, financial results, biopharmaceutical, research and development